Our current CoBi research projects

Here you find an overview and summaries on research projects using the CoBi resources.

Project Title Impact of KIR2DS1 and KIR3DL1 donor gene content on outcome after allogeneic hematopoietic cell transplantation for patients with myeloid neoplasia
Principal Investigator Prof. Dr. Johannes Schetelig
Links

Presentation at the ASH meeting 2018

Poster ASH meeting 2018

Summary Improved donor selection based on immune-genetic markers may improve outcome after allogeneic hematopoietic cell transplantation (alloHCT). Until now, information on the degree of HLA-compatibility, donor age, donor sex and ABO blood group is considered for donor selection. A recent series of publications suggests that harnessing natural killer (NK) cell reactivity could further improve outcome after alloHCT. Especially, the presence of KIR2DS1 genes in the donor genome and advantageous combinations of KIR3DL1 donor content and HLA-Bw4 ligands in the patient have been associated with a reduced risk of relapse. This study aims at a validation of these recently reported findings.

 

Project Title Retrospective Study on Immunosurveillance by NK- and T-cells of leukemogenesis in AML
Principal Investigator Prof. Dr. Johannes Schetelig
Links  
Summary The immunologic control of nascent leukemia is incompletely understood. T-cells can recognize intracellular antigens, presented by HLA-class I molecules, which derive from mutated oncoproteins. Tumor cells can downregulate HLA-class I molecules from the cell surface and thereby evade T-cell recognition. In this situation, Natural Killer (NK) cells can take over immune control. Via Killer-Immunoglobulin-like Receptors (KIR) these cells receive inhibitory signals when they encounter self HLA-class-I molecules. If this signal is missing, NK-cells may kill the target cells.
With this study we want to test the hypothesis, that T-cell mediated immune surveillance depends on the individual HLA-repertoire. In analogy, NK-cell mediated immune control may depend on the individual KIR-repertoire. These hypotheses shall be tested by comparing the HLA- and KIR-repertoire of patients with AML to the repertoire of the corresponding general population. The study design represents a case-control study. Existing samples from patients with AML will be typed for HLA- and KIR-genes and the results will be compared to reference values. This retrospective study does not require the collection of new samples or of medical data. Results of this study may give insights to the role of T- and NK-cell mediated leukemia control and may instruct donor selection for future adoptive cellular therapies.

 

 

  • Logo DKMS - Wir besiegen Blutkrebs
  • Logo cellex. Cell Professionals
  • Logo Universitätsmedizin Mannheim
  • Logo Universitätsklinikum Frankfurt Goethe Universität
  • Logo Universitätsmedizin Greifswald
  • Logo Klinikum Nürnberg
  • Logo Universitätsklinikum Tübingen
  • Logo Technische Universität Dresden
  • Logo TMF
  • Logo LSL
  • Logo Universitätsklinikum Münster
  • Logo Robert-Bosch-Krankenhaus